Takeda Launches CDPATH™, a Personalized Prognostic Tool, Advancing Innovation for Patients with Crohn's Disease
/PRNewswire/ -- Takeda (TSE:4502/NYSE:TAK) today announced the national launch of the CDPATH™ program, which includes an innovative, validated personalized...
Source: prnewswire.com